A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

Prior treatment

• Patient enrolled in a prospective interventional clinical trial assessing an investigational product.

Other

• For a patient alive at the moment of the inclusion in the study: patient without liberty, under tutelage, or unable to give oral consent.

• Patient ≥ 18 years of age
• Patient with locally advanced or metastatic urothelial carcinoma (irrespective of tumor histology) whose disease has not progressed (ongoing stable disease, partial response or complete response) following completion of first-line platinum-based chemotherapy and who has been (retrospective), is (retrospective and prospective), will be (prospective) treated with avelumab.
  • For a patient alive at the moment of the inclusion in the study : the patient must be informed of the study, he/she must be given an information letter signed by the investigator and must not be opposed to the collection of his/her data
  • For a patient who died before the inclusion in the study : the patient (during his life time) must not be opposed in writing to the collection of his data.
• Patient benefiting from a social security scheme according to local regulations